These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18622936)

  • 1. [Safety and efficacy of biologics directed against TNF-alpha and CD20 in the therapy of vasculitis and systemic lupus erythematosus].
    Walker UA; Hasler P
    Ther Umsch; 2008 May; 65(5):303-10. PubMed ID: 18622936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases.
    Lamprecht P
    Autoimmun Rev; 2005 Jan; 4(1):28-34. PubMed ID: 15652776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New treatments for systemic diseases].
    Bader-Meunier B; Willems M
    Arch Pediatr; 2006 Jun; 13(6):596-8. PubMed ID: 16690273
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.
    Walsh M; Jayne D
    Kidney Int; 2007 Sep; 72(6):676-82. PubMed ID: 17609693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A; White AJ
    Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current state of biologicals in the management of systemic vasculitis.
    Lamprecht P; Till A; Steinmann J; Aries PM; Gross WL
    Ann N Y Acad Sci; 2007 Sep; 1110():261-70. PubMed ID: 17911441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases.
    Langford CA
    Nat Clin Pract Rheumatol; 2008 Jul; 4(7):364-70. PubMed ID: 18506159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging biological therapies in systemic lupus erythematosus.
    Mount GR; Gilliland WR
    Clin Pharmacol Ther; 2008 Jan; 83(1):167-71. PubMed ID: 18000515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
    Feldmann M; Pusey CD
    J Am Soc Nephrol; 2006 May; 17(5):1243-52. PubMed ID: 16624928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M; Fujii K; Saito K; Nakayamada S; Tsujimura S; Nawata M; Tanaka Y
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of autoimmune thrombocytopenic purpura with rituximab in a dialysis patient with systemic lupus erythematosus.
    Lee SY; Hsu PY; Juan KC; Chang H; Huang WH; Lai PC
    Int Immunopharmacol; 2010 May; 10(5):632-4. PubMed ID: 20172055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.